Abstract
Growth is a fundamental part of childhood and reflects the complex interactions of environmental, hormonal, and genetic factors. Assessment of growth is an essential component in monitoring childhood health and development. During the first few years of life, a child’s height can cross percentile lines on a growth chart, reflecting, at least in part, his or her genetic makeup. After this time, children grow in a relatively predictable manner and deviation from a normal growth pattern may reflect an underlying chronic disorder. Accurate growth measurements should therefore be a part of the routine pediatric examination.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Whitehouse RH, Tanner JM, Healy MJR. Diurnal variation in stature and sitting height in 12-14 year old boys. Ann Hum Biol 1974; 1:103–106.
Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford University Press, Stanford, CA, 1959.
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40:423–441.
Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64:51–58.
Carlsson LMS, Attie KM, Compton PG, et al. Reduced concentrations of serum GHBP in children with idiopathic short stature. J Clin Endocrinol Metab 1994; 78:1325–1330.
Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49:825–836.
Rinderknecht E, Humbel RE. The amino sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253:2769–2776.
Rinderknecht E, Humbel RE. Primary structure of human insulin-like growth factor II. FEBS Lett 1978; 89:283-286.
Brissenden JE, Ullrich A, Francke U. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 1984; 310:781–784.
Tricoli JV, Rail LB, Scott J, et al. Localization of human insulin-like growth factor genes to human chromosomes 11 and 12. Nature 1984; 310:784–785.
Luna AM, Wilson DM, Wibbelsman CJ, et al. Somatomedins in adolescence: a cross-sectional study of the effect of puberty on plasma insulin-like growth factor I and II Levels. J Clin Endocrinol Metab 1983; 57:258–271.
Hintz RL, Liu F. A radioimmunoassay for insulin-like growth factor-II specific for the C-peptide region. J Clin Endocrinol Metab 1982; 54:442–446.
Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982; 257:5038–5045.
Rosenfeld RG, Hintz RL. Somatomedin receptors: structure, function and regulation. In: Conn M, ed. The Receptors. Academic, New York, 1986; pp. 281–329.
MacDonald R, Pfeffer SR, Coussens L, et al. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science 1988; 239:1134-1137.
Rosenfeld RG, Conover CA, Hodges D, et al. Heterogeneity of insulin-like growth factor-I affinity for the insulin-like growth factor-II receptor: comparisonm of natural, synthetic and recombinant DNA derived insulin-like growth factor I. Biochem Biophys Res Commum 1987; 143:195–205.
Cohen P, Rosenfeld RG. Physiologic and clinical relevance of the insulin-like growth factor binding proteins (review). Cur Opinion Peds 1994; 6:462-467.
Martin GL, Baxter RC. Insulin-like growth factor binding protein from human plasma. Purification and characterization. J Biol Chem 1986; 261:8754–8760.
Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding howmone complex. J Clin Endocrinol Metab 1988; 67:265–272.
Spranger J. International classification of osteochondrodysplasias. Eur J Pediatr 1992; 151: 407-415.
Rivkees SA, Bode HH, Crawford JD. Long-term growth in juvenile acquired hypothyroidism. N Engl J Med 1988; 318:599–602.
Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis and therapy. N Engl J Med 1994; 331:629–636.
Katz HP, Youlton R, Kaplan SL, et al. Growth and growth hormone. III. Growth hormone release in children with primary hypothyroidism and thyrotoxicosis. J Clin Endocrinol Metab 1969; 29:346.
Fratz AG, Rabkin MT. Human growth hormone. Clinical measurement, response to hypoglycemia and suppression by corticosteroids. N Engl J Med 1964; 271:1375.
Thompson RG, Rodriguez A, Kowarski A, et al. Growth hormone: metabolic clearance rates in normal adults and effect of prednisone. J Clin Invest 1972; 51:3193–3199.
Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic Controversy: The diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532–1540.
Reiter EO, Morris AH, MacGillivray MH, et al. Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab 1988; 66:68–71.
Spiliotis BE, August GP, Hung W, et al. Growth neurosecretory dysfunction: a treatable cause of short stature. JAMA 1984; 252:2223–2230.
Delier, Jr JJ, Boulis MW, Hariss WE, et al. Growth hormone response patterns to sex hormone administration in growth retardation. Am J Med Sci. 1970; 259:292–296.
Marin G, Domene HM, Barnes KM, et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994; 79:537–541.
Underwood LE, D’Ercole AJ, Van Wyk JJ. Somatomedin-C and the assessment of growth. Pediatric Clin North Am. 1980; 27:771–782.
Rosenfeld RG, Wilson DM, Lee PDK, et al. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr. 1986; 109:428–433.
Magalam HJ, Albert VR, Ingraham HA, et al. A pituitary POU domain protein, pit-1, activates both growth hormone and prolactin promoters transcriptionally. Genes Dev 1989; 3:946–958.
Pfaffle RW, DiMattia E, Parks JS, et al. Mutations of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992; 257:1118–1121.
Rosenfeld RG, Northcraft GB, Hintz RL. A prospective, randomized trial of testosterone treatment of constitutional short stature in adolescent males. Pediatrics 1982; 69:681–687.
Frasier SD. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 1983;4:155–170.
Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336:285–288.
Fradkin JE. Creutzfeldt-Jacob disease in pituitary growth hormone recipients. Endocrinologist 1993; 3:108–114.
Hintz RL. Untoward events in patients treated with growth hormone in the USA. Horm Res 1992; 38(suppl 1):44–49.
Fisher DA, Job JC, Preece M, et al. Leukemia in patients treated with growth hormone. Lancet 1988; 1:1159–1160.
Guler HP, Schmid C, Zapf J, et al. Effects of recombinant insulin-like growth factor-I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989; 86:2868–2872.
Laron Z, Klinger B, Jensen JT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf) 1991; 35:145–150.
Laron Z, Anin S, Klipper-Auerbach Y, et al. Effects of insulin-like growth factor-I on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339:1258–1261.
Walker J, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor-I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121:641–646.
Savage MO, Wilton P, Ranke MB, et al. Therapeutic response to recombinant IGF-I in thirty-two patients with growth hormone insensitivity. Pediatr Res 1993; 33:S5 (abstract).
Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized, doulbe-blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80(4): 1393–1398.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Humana Press Inc.
About this chapter
Cite this chapter
Hunten, M.K., Rosenfeld, R.G. (1997). Growth Hormone Deficiency. In: Wierman, M.E. (eds) Diseases of the Pituitary. Contemporary Endocrinology, vol 3. Humana Press. https://doi.org/10.1007/978-1-4612-3954-3_6
Download citation
DOI: https://doi.org/10.1007/978-1-4612-3954-3_6
Publisher Name: Humana Press
Print ISBN: 978-1-4612-8438-3
Online ISBN: 978-1-4612-3954-3
eBook Packages: Springer Book Archive